Optibiotix Health launches first product from Seed collaboration

Life sciences firm Optibiotix Health on Thursday launched a new product in the US that contains its LPLDL cholesterol-reducing and blood pressure-reducing strain.

The product is the first to be launched since Optibiotix and Seed Health entered into a non-exclusive agreement to produce, promote, market and commercialise products containing LPLDL in the US on 22 May.

Stephen O'Hara, chief executive of OptiBiotix, said: "We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market. The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world."

The AIM-traded company described LPLDL as an "innovative product concept" which combines multiple strains of various probiotics which have been selected because of strong clinical trial data.

The product will be marketed by Seed under the brandname Daily Synbiotic and is available to customers directly through the company website.

"We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world," said O'Hara.

As of 0917 BST, Optibiotix Health’s shares were unchanged at 70.50p.